Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
KUALA LUMPUR (March 31): Duopharma Biotech Bhd (KL:DPHARMA) could soon secure a new contract to supply human insulin formulations to the government, according to TA Securities.
The company could get a three-year contract when the interim three-month extension expires on May 15, the research house said in a note. The deal could be awarded under a dual-supplier arrangement between Duopharma and Pharmaniaga Bhd (KL:PHARMA), the research house added.
“We expect the group to secure a new three-year contract in the near term,” TA Securities said.
Under the previous contract, about 80% of the government’s human insulin supply was sourced from Biocon via Duopharma, while the remaining 20% came from Novo Nordisk, which has exited the human insulin market.
The Ministry of Health’s policy requires at least two suppliers for procurement of off-patent drugs and medical devices. The ministry is also offering three-year contracts to local companies to encourage production of critical off-patent drugs.
Jason, if big institutions come in ( EPF, kwap or others ) got chance will fly as they come in for a long time. Hoping as the business progresses with their new plants and concentrate on manufacturing will go up. It’s a need business so hope is there.
